A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, Phase 2a, open-label, 2-part study to investigate the safety,
tolerability, and anti-tumor activity of ZW25 (zanidatamab) in combination with palbociclib
plus fulvestrant. Eligible patients include those with locally advanced (unresectable) and/or
metastatic human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor
(HR)-positive breast cancer.